title: [The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].
abstract: BACKGROUND
  Multiple myeloma is an incurable hematological disease. High-dose chemotherapy including autologous stem cell transplantation is recently considered a standard therapy for myeloma. Unfortunately, a relapse of the disease is inevitable. Therefore, new approaches such as immunotherapy have been considered recently. A specific activation of cytotoxic T cells can be reached using dendritic cells loaded with tumor-specific antigens. The HLA-A2-specific nonapeptides as hTERT derived from catalytic subunit of telomerase and MUC1 derived from mucin protein can be used.
  
  
  METHODS
  Activation, identification, separation and expansion of myeloma-specific T cells from healthy HLA-A2 blood donors were tested in an in vitro study using hTERT and MUC1 nonapeptides as tumor-specific antigens.
  
  
  RESULTS
  T cells and dendritic cells were obtained from peripheral blood. T cells were repeatedly stimulated with hTERT and MUC1 nonapeptide-loaded dendritic cells. Activated myeloma-specific T cells produced interferon gamma and were evaluated by flow cytometry. The activated T cells were immunomagnetically separated and in vitro expanded to the number usable in clinical trials.
  
  
  CONCLUSIONS
  This study demonstrates feasibility of a specific activation, identification, separation and expansion of tumor-specific T cells that can be used in myeloma therapy.
authors.affiliation: Laborator experimentální hematologie a bunecné imunoterapie, Oddelení klinické hematologie, FN Brno. jennynka@seznam.cz
authors.forename: D
authors.initials: D
authors.lastname: Ocadlíková
authors.forename: L
authors.initials: L
authors.lastname: Kovárová
authors.forename: R
authors.initials: R
authors.lastname: Hájek
authors.forename: J
authors.initials: J
authors.lastname: Michálek
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines; D003713:Dendritic Cells / Q000276:immunology*; D000939:Epitopes; D006801:Humans; D007167:Immunotherapy; D008213:Lymphocyte Activation; D018396:Mucin-1 / Q000276:immunology*; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D019098:Telomerase / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes; D018396:Mucin-1; C509186:TERT protein, human; D019098:Telomerase